Amends existing law to classify mifepristone and misoprostol as schedule IV drugs.
Summary
House Bill 137 amends Idaho’s Uniform Controlled Substances Act to add mifepristone and misoprostol to the state’s Schedule IV list of controlled substances. The bill places those two drugs alongside other prescription depressants and related medications already classified in Schedule IV, and it declares an emergency so the change would take effect on July 1, 2025.
The practical effect is to make possession, distribution, and prescribing of mifepristone and misoprostol subject to Idaho’s controlled-substances framework, unless otherwise exempted under existing law or future rulemaking. Because these drugs are commonly associated with medication abortion and also have other medical uses, the bill would affect patients, prescribers, pharmacists, and law-enforcement/regulatory agencies by changing how the drugs are treated under state drug law.
Impact
The bill amends Section 37-2711, Idaho Code, which defines Schedule IV controlled substances, by inserting mifepristone and misoprostol into the statutory list. This would expand the scope of Idaho’s controlled-substances law to cover those medications and could subject them to the regulatory, enforcement, and criminal-law consequences that attach to Schedule IV drugs. The bill also includes an emergency clause, making the amendment effective immediately on July 1, 2025, rather than waiting for a standard delayed effective date.
Sentiment
Based on the bill’s subject matter and the absence of recorded committee debate or votes in the provided materials, the available context suggests the measure is a straightforward committee-sponsored policy change rather than a broadly negotiated compromise. The bill text itself is direct and categorical, indicating a clear intent to reclassify the drugs without additional procedural detail. Because no transcripts or vote history are provided, there is no documented legislative sentiment beyond the bill’s introduction and drafting.
Contention
The main point of contention is the reclassification of mifepristone and misoprostol, which are widely known as medications used in abortion care but also have other medical applications. Supporters would likely view the bill as a controlled-substances policy measure, while opponents would likely argue that it is an attempt to restrict access to reproductive-health medications through drug scheduling. The lack of committee transcripts means no specific arguments, amendments, or named legislators are available, but the subject matter itself suggests the bill is likely to be politically and medically controversial.